GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » EV-to-EBIT

I-MAB (IMAB) EV-to-EBIT : 0.74 (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, I-MAB's Enterprise Value is $-151.19 Mil. I-MAB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-204.85 Mil. Therefore, I-MAB's EV-to-EBIT for today is 0.74.

The historical rank and industry rank for I-MAB's EV-to-EBIT or its related term are showing as below:

IMAB' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.92   Med: 0.65   Max: 65.54
Current: 0.74

During the past 7 years, the highest EV-to-EBIT of I-MAB was 65.54. The lowest was -10.92. And the median was 0.65.

IMAB's EV-to-EBIT is ranked better than
69.59% of 434 companies
in the Biotechnology industry
Industry Median: 9.44 vs IMAB: 0.74

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. I-MAB's Enterprise Value for the quarter that ended in Dec. 2023 was $-147.89 Mil. I-MAB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-204.85 Mil. I-MAB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 138.52%.


I-MAB EV-to-EBIT Historical Data

The historical data trend for I-MAB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB EV-to-EBIT Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - 35.79 -8.55 0.38 0.72

I-MAB Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.55 - 0.38 - 0.72

Competitive Comparison of I-MAB's EV-to-EBIT

For the Biotechnology subindustry, I-MAB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where I-MAB's EV-to-EBIT falls into.



I-MAB EV-to-EBIT Calculation

I-MAB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-151.191/-204.852
=0.74

I-MAB's current Enterprise Value is $-151.19 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. I-MAB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-204.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB  (NAS:IMAB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

I-MAB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-204.852/-147.88996
=138.52 %

I-MAB's Enterprise Value for the quarter that ended in Dec. 2023 was $-147.89 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. I-MAB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-204.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of I-MAB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB (IMAB) Business Description

Traded in Other Exchanges
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.